Although disruption of histone modification patterns is a common hallmark of human cancer, our knowledge of the mechanistic role of histone-modifying enzymes in its generation is very limited. We have recently identified an inactivating mutation in the histone deacetylase-2 (HDAC2) in sporadic carcinomas with microsatellite instability and in tumors arising in individuals with hereditary nonpolyposis colorectal cancer syndrome. Since HDAC2 seems to be a central player in epigenetic gene repression, we wondered whether HDAC2-truncating mutations conferred a particular expression signature on these cancer cells. Using unsupervised clustering analysis in microsatellite-unstable colorectal cancer cell lines, we have found that HDAC2 mutant cells (RKO and Co115) show a characteristically different expression microarray signature from HDAC2 wild-type cells (HCT-116, SW48, HCT-15 and LoVo). HDAC2 mutant cells exhibit upregulation of tumor-promoting genes, such as those of tyrosine kinases, mediators of cell cycle progression and angiogenic factors. The overexpression of these genes is associated with a loss of HDAC2 recruitment and a gain of histone H4 hyperacetylation in their particular 5 0 -end promoters, as observed by chromatin immunoprecipitation. Transfection of wild-type HDAC2 in mutant cells reverted this epigenetic pattern by repressing the transforming genes in association with HDAC2 promoter occupancy. These results suggest a role for HDAC2 mutations in human tumorigenesis through the derepression of key genes from multiple cellular transformation pathways.
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Our knowledge of the behavior of histones in cancer cells is very limited. We know that certain histone modifications participate in tumor-suppressor gene silencing, in conjunction with CpG island hypermethylation (Nguyen et al., 2001; Fahrner et al., 2002; Ballestar et al., 2003) , or in its absence, such as the case of p21 WAF1 (Richon et al., 2000) . Most importantly, we have recently demonstrated that human tumors undergo an overall loss of monoacetylation of lysine 16 and trimethylation of lysine 20 in the tail of histone H4 (Fraga et al., 2005) . Certain histone acetylation and methylation markers may also have prognostic value (Seligson et al., 2005) . Thus, it is worth considering whether there are genetic lesions that originate or expand the patterns of aberrant histone acetylation of the cancer cell.
Histone acetylation levels result from the balance of two enzymatic activities, that is, histone acetyl transferases and histone deacetylases (HDACs). Eighteen mammalian HDAC enzymes have been identified so far, and these can be classified into three different families according to their homology with yeast HDACs (Glozak and Seto, 2007; Ropero and Esteller, 2007) . The most thoroughly studied HDACs are mammalian class I deacetylases, particularly, HDAC1 and HDAC2. Both are ubiquitously expressed with nuclear localization and are components of multiprotein complexes with transcriptional repression activity, participating in the regulation of cell cycle, differentiation and development (Glozak and Seto, 2007; Ropero and Esteller, 2007) .
Our understanding of the role of HDACs in human cancer is still at a very early stage (Glozak and Seto, 2007; Ropero and Esteller, 2007) . However, we have recently discovered a truncating mutation of HDAC2 in tumors with microsatellite instability that leads to the loss of HDAC2 expression and enzymatic activity (Ropero et al., 2006) , and renders these cells more resistant to treatment with the classical HDAC inhibitor trichostatin A (Ropero et al., 2006) . Furthermore, the ectopic expression of HDAC2 in mutant cancer cells induces reduction of colony formation and the inhibition of tumor growth in xenograft nude mice (Ropero et al., 2006) , suggesting a putative tumor-suppressor role for HDAC2 in this cellular setting. In support of this idea, it is known that the tumor-suppressor gene Rb represses gene transcription by recruiting class I HDACs (Frolov and Dyson, 2004) , indicating that HDAC2 mutations could induce the derepression of Rb-silenced genes. Interestingly, in the context of microsatellite stable colorectal tumors, elevated expression of HDAC2 is observed (Zhu et al., 2004) . HDAC1 and HDAC2 double-null mice show an uncontrolled proliferation of ventricular cardiomyocytes (Montgomery et al., 2007) ; however, there is lack of the cardiac hypertrophic response in HDAC2 mutant mice (Trivedi et al., 2007) . Thus, since HDAC2 seems to be a central player in epigenetic gene repression, we wondered whether HDAC2-truncating mutations conferred a particular expression signature on these cancer cells that facilitated their progress to tumorigenesis.
To this end, we extracted and analyzed total mRNA from six colorectal cancer cell lines with microsatellite instability, two HDAC2 mutant (RKO and Co115) and four HDAC2 wild-type (SW48, HCT-116, HCT-15 and LoVo) cell lines, using the HGU133A2.0 Affymetrix GeneChip microarrays, which represent 22 277 probe sets. Cluster analysis using the Self-Organizing Hierarchical Neural Network (SOTA) (Dopazo and Carazo, 1997) , an unsupervised neural network with a binary tree topology, demonstrated that the colorectal cancer Figure 1 Gene-expression profile in microsatellite-unstable colon cancer cell lines according to histone deacetylase-2 (HDAC2) mutational status. (a) Dendrogram representing the unsupervised cluster analysis of colorectal cancer cell lines. Data sets used for hierarchical clustering were normalized by standardizing the expression level of each gene and each sample to mean ¼ 0 and variance ¼ 1. Cluster analysis was performed using the Self-Organizing Hierarchical Neural Network (SOTA), an unsupervised neural network with a binary tree topology, which combines the advantages of divisive and customizable methods. In all cases, the linear correlation coefficient was used. The output file was visualized as a binary tree with the TREEVIEW program. The matrix values were transformed into a graded color pattern (red through black to green, representing the mean adjusted ratio of each point of the matrix. These programs are available online at http://gepas.bioinfo.cnio.es/cgi-bin/sotarray. (b) Gene ontology distribution of the 121 genes significantly upregulated in HDAC2 mutant cells (Mann-Whitney Po0.01, and greater than twofold average change) using the BINGO program for molecular and cellular functions. (c) SYBR green real-time reverse transcriptase (RT)-PCR analysis of 10 upregulated candidate genes in wild-type (HCT-116) and mutant (RKO, Co115) HDAC2 colon cancer cells. A 2 mg portion of total RNA isolated using TRIzol (Life Technologies, Gaithersburg, MD, USA) was reverse-transcribed using SuperScript II reverse transcriptase (Gibco/ BRL), and PCR was performed with primers specific for the cDNA of the indicated genes (Supplementary Table 2 ).
cell lines harboring the truncated form of HDAC2 are grouped in a significantly different branch from those carrying the HDAC2 wild-type gene (Figure 1a) . From a gene point of view, the HDAC2 mutant RKO and Co115 cells show common upregulation of 121 genes with respect to all the four HDAC2 wild-type cells (SW48, HCT-116, HCT-15 and LoVo) (Mann-Whitney Po0.01, and greater than twofold average change). The complete list of upregulated genes in HDAC2 mutant cells is provided in Supplementary Table 1 . In contrast, only 74 genes were downregulated in HDAC2-disrupted cells with respect to HDAC2-intact cells. These findings are consistent with the generally accepted idea that HDAC2 acts mainly as a transcriptional repressor, as discussed above. The gene ontology analysis of the upregulated genes found in HDAC2 mutant cancer cell lines shows that multiple networks and molecular pathways are affected upon HDAC2 disruption, from gene transcription and signal transduction to cell adhesion, apoptosis, angiogenesis and cell cycle progression (Figure 1b) . We selected 10 candidates (Table 1) from the significantly upregulated genes in HDAC2 mutant cells (Supplementary Table 1 ) for further analyses. These candidates were chosen because they were representatives of a wide range of pathways in tumor development and metastasis, such as receptor tyrosine kinases (EPHA2), regulation of cell cycle progression (PPP2R4 and PPP2R1B9), angiogenesis (TNFAIP2) and regulation of tumor suppressors (MDM2), among others. We first validated the expression levels of the 10 genes by realtime reverse transcriptase (RT)-PCR. We observed that the HDAC2 mutant cell lines (RKO and Co115) expressed higher levels of the corresponding transcripts than did the HDAC2 wild-type cell lines (HCT-116, HCT-15, SW48 and LoVo) (Figure 1c) .
Once the upregulation of these genes had been confirmed, we attempted to elucidate the underlying mechanism. Two possible scenarios are possible for each gene; first, their overexpression in HDAC2 mutant cells is caused by the loss of direct binding of HDAC2 to the corresponding promoter, or second, this occurs because HDAC2 is not bound to an upstream regulatory protein, which leads to the upregulation of downstream targets. To determine which of these was the case, we performed chromatin immunoprecipitation (ChIP) analysis of the HDAC2 protein. Our analysis of HDAC2 in the 10 candidate genes confirmed both scenarios, that is, 60% (6 of 10) of the HDAC2 mutant upregulated genes presented HDAC2 occupancy in the corresponding 5 0 -regulatory regions in the HDAC2 wild-type cells (HCT-116), but loss in the HDAC2 mutants (RKO and Co115) (Figure 2a ). In the remaining four genes (PDX-1, FIBP, TNFAIP2 and MDM2), HDAC2 was absent from both wild-type and mutant cells (Figure 2b) , suggesting an indirect effect mediated by other transcription factors that are themselves directly regulated by HDAC2.
We proceeded to characterize further the chromatin context of the six upregulated genes that were found to be directly regulated by HDAC2, that is, PPP2R4, PPP2R1B, RBPMS, NCOA4, CORO1C and EPHA2. The ChIP assay revealed that the loss of HDAC2 recruitment to the corresponding promoters in the colorectal mutant cells was associated with an increase in histone H4 and H3 acetylation; histone modification markers were associated with active transcription (Figure 2c ) (Strahl and Allis, 2000; Kouzarides, 2007) . On the other hand, HDAC2 wild-type cells showed hypoacetylated histones H4 and H3 at these 5 0 -regulatory region in concordance with a state of transcriptional repression (Figure 2c ) (Strahl and Allis, 2000; Kouzarides, 2007) .
Finally, we wondered whether it was possible to revert the described epigenetic and expression phenotype of HDAC2 mutant cells by reintroducing the HDAC2 enzyme into the deficient cells. To address this, we transfected the HDAC2 mutant cell line RKO with the HDAC2 full-length cDNA (pcDNA3-HDAC2) or the empty vector (pcDNA3) (Figure 3a and Supplementary  Figure 1) . HDAC1 expression was similar in all cells (Figure 3a) . We observed that the expression of the directly upregulated genes of the HDAC2 mutant (PPP2R4, PPP2R1B, RBPMS, NCOA4, CORO1C and EPHA2) became significantly downregulated in the HDAC2-transfected cells (Figure 3b ) in association with increased binding of HDAC2 to their corresponding promoters (Figure 3c ). On the contrary, HDAC2 depletion by short interference RNA (siRNA) in the HCT-116 wild-type cells induced overexpression of the described candidate genes (Figure 3d ). Depletion of HDAC1 by siRNA in HCT-116 cells did not induce increased expression of the HDAC2-target genes (data not shown).
Overall, our results suggest that the presence of HDAC2 mutations in colorectal cancer cells leads to a global dysregulation of gene expression, characterized by the upregulation of tumor-growth-promoting genes. The overexpression of these transforming genes is caused by both indirect and direct mechanisms, the latter involving loss of recruitment of HDAC2 and hypoacetylated histones H4 and H3 in the corresponding 5 0 -regulatory regions. The restoration of transcriptional repression of these target genes by the artificial reintroduction of wild-type HDAC2 in mutant cells reflects the dynamic nature of the epigenetic changes. Furthermore, it suggests a possible direction for future therapeutic interventions by attempting to recover the physiological histone modification patterns lost in human tumors.
